Certepetide plus chemotherapy showed signs of efficacy but failed to improve progression-free survival in metastatic PDAC in ...

Adding CRT to chemotherapy did not improve RFS in resected gallbladder cancer in the phase 3 ACCELERATE trial.

Virginia G. Kaklamani, MD, DSc, discusses datopotamab deruxtecan and other antibody-drug conjugates available for patients with unresectable or metastatic hormone receptor-positive, HER2-negative ...

Surufatinib plus TAS-102 showed promising survival benefits with manageable toxicity in refractory metastatic PDAC patients, ...

Ajay Goel, PhD, AGAF, discusses how the development and validation of novel non-invasive biomarkers can improve early detection and ultimately impact patient outcomes for patients.

The combination of treosulfan and fludarabine as a preparative regimen for allogeneic hematopoietic stem cell transplantation ...

The phase 3 REGAL trial of galinpepimut-S in acute myeloid leukemia can proceed without modifications, based on findings from ...

Panelists discuss how to optimize treatment selection and sequencing for a 65-year-old patient with standard-risk, transplant ...

Panelists discuss how the IMROZ trial demonstrated improved outcomes with quadruplet therapy combining daratumumab, lenalidomide, melphalan, and prednisone in patients with transplant-ineligible newly ...

The phase 3 CheckMate 649 trial showed that nivolumab plus chemotherapy significantly improved long-term overall survival in Chinese patients with advanced gastric, gastroesophageal junction, and ...

CheckMate 649 trial showed sustained efficacy with frontline nivolumab plus chemotherapy vs chemotherapy alone in patients with gastric cancers.

David M. Waterhouse, MD, MPH, and Molly Mendenhall, MBOE, LSSBB, BSN, RN, discuss how the implementation of Lean Six Sigma methodology at Oncology Hematology Care in Cincinnati, Ohio, has transformed ...